MS patients switch drugs in Cost-Saving move: does it work?
NCT ID NCT07235644
Summary
This study looks at what happens when people with relapsing-remitting multiple sclerosis (MS) switch from the drug MabThera to a very similar, potentially cheaper version called Rixathon. Researchers are checking if the switch affects disease activity, safety, or disability progression by reviewing the medical records of 184 patients who made this change. They are analyzing existing data like blood tests, MRI scans, and symptom records collected before and after the switch.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uppsala University Hospital
Uppsala, Sweden
Conditions
Explore the condition pages connected to this study.